SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Baxalta US Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Lewis B. Silverman, M.D., Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01574274
First received: April 5, 2012
Last updated: February 12, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)